TetraLogic Pharmaceuticals Corp
OTC:TLOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TetraLogic Pharmaceuticals Corp
OTC:TLOG
|
US |
|
A
|
Arnoldo Mondadori Editore SpA
MIL:MN
|
IT |
|
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
|
TR |
|
O
|
OK Play India Ltd
BSE:526415
|
IN |
|
W
|
Windward Ltd
LSE:WNWD
|
IL |
|
Oportun Financial Corp
NASDAQ:OPRT
|
US |
TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
